2009
HIV Incidence Rates and Risk Factors for Urban Women in Zambia: Preparing for a Microbicide Clinical Trial
Kapina M, Reid C, Roman K, Cyrus-Cameron E, Kwiecien A, Weiss S, Vermund SH. HIV Incidence Rates and Risk Factors for Urban Women in Zambia: Preparing for a Microbicide Clinical Trial. Sexually Transmitted Diseases 2009, 36: 129-133. PMID: 19174729, PMCID: PMC2889146, DOI: 10.1097/olq.0b013e318190191d.Peer-Reviewed Original ResearchConceptsHigh HIV prevalenceHIV prevalenceHIV incidenceIncidence rateHighest age-specific prevalenceHuman immunodeficiency virus (HIV) incidencePreparedness studiesBaseline HIV prevalenceRisk reduction counselingAge-specific prevalenceHIV incidence ratesMicrobicide clinical trialsWomen yearsSexual behavioral characteristicsPopulation of womenSame study proceduresGeneral population sampleHIV acquisitionReduction counselingEligible womenHIV/Infection testingRisk factorsClinical trialsPregnancy rate
2001
Vaccine Efficacy Trials for Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Are Feasible in the United States: A Commentary on the HIVNET Vaccine Preparedness Study
Vermund SH. Vaccine Efficacy Trials for Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Are Feasible in the United States: A Commentary on the HIVNET Vaccine Preparedness Study. American Journal Of Epidemiology 2001, 153: 628-631. PMID: 11282788, DOI: 10.1093/aje/153.7.628.Peer-Reviewed Original Research
1998
Rationale for the testing and use of a partially effective HIV vaccine.
Vermund SH. Rationale for the testing and use of a partially effective HIV vaccine. AIDS Research And Human Retroviruses 1998, 14 Suppl 3: s321-3. PMID: 9814960.Peer-Reviewed Original Research